With a Ph.D.-level research team and years of experience in ADC development and production, BOC Sciences's ADC manufacturing platform will provide a variety of payloads for your ADC projects, driving advances in clinical trials. Antibodies-Drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves tumor-specific antibodies, linkers and cytotoxic payloads. The payload in the ADC is a highly efficient cytotoxin that plays a role in the key cellular processes required for survival. Generally, the cytotoxin used in the ADC is 100-1000 times more potent than conventional chemotherapeutic agents, and preferably has a subnanomolar potency.
Some payloads work by destroying the structure of DNA. For example, calicheamicins is an effective anti-tumor antibiotic. The anti-tumor mechanism is to form a double strand break of a specific site through the combination of tiny grooves in DNA. Double strand DNA damage inhibited DNA synthesis and led to the death of leukemia cells. In addition to the previously mentioned payloads, new chemical or biochemical entities are also used as payloads, which trigger specific downstream processes and cause cell damage, including drug carriers, toxic proteins, toxic enzymes, and small molecular inhibitors for other key cellular pathways.
BOC Sciences has a list of potent cytotoxic payloads and can create a series of ADCs with different payloads for customers to screen. It is also possible to provide customers with a payload linker that enables them to engage on their own. BOC Sciences can also design and synthesize effective cytotoxic compounds and payloads.